[1] 中华人民共和国卫生部.卫生部发布2012年1月及2011年度全国法定传染病疫情概况[EB/OL]. 2012.http://www.moh.gov.cn/publicfiles/business/Htmlfiles/mohjbyfkzj/s3578/201202/54106.htm
[2] Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int, 2012,6:409-435.
[3] Raimondi S, Bruno S, Mondelli MU, et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol, 2009,50:1142-1154.
[4] Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat, 2011,18:745-759.
[5] McMahon BJ, Bruden D, Bruce MG, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology,2010, 138:922-931.
[6] Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat, 2011,18:e516-e522.
[7] van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 2012,308:2584-2593.
[8] Kanwal F,Kramer JR,Ilyas J,et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans With HCV. Hepatology, 2014, 60:98-105.
[9] Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype l patients:A randomized controlled trial.Hepatology,2008,47:43-50.
[10] McHutchison JG,Lawitz EJ,Shiffman ML,et al.Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treament of Hepatitis C Infection. N Eng J Med,2009,361:580-593.
[11] Ferenci P, Brunner H, Laferl H, et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology, 2008, 47:1816-1823.
[12] Borroni G, Andreoletti M, Casiraghi MA, et al. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther, 2008, 27:790-797.
[13] Berg T, Carosi G. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther, 2008, 13 Suppl 1:17-22.
[14] Elefsiniotis IS, Pantazis KD, Dimitroulopoulos D, et al. Impact of shorter duration of treatment on virological response rate in genotype 2 or 3 chronic hepatitis C virus infection. Indian J Gastroenterol, 2007, 26:209-213.
[15] Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet,2001,358:958-965.
[16] Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med,2002,347:975-982.
[17] Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patints. Gstroenterology,2005,128:636-641.
[18] Dalgard O, Bjro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology, 2008, 47:35-42.
[19] Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol, 2008, 48:28-34.
[20] Rumi MG, Aghemo A, D'Ambrosio R, et al. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Ther, 2007, 12:1033-1040.
[21] Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med, 2007, 357:124-134. |
